이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aadi Bioscience 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Dave Lennon

최고 경영자

US$2.1m

총 보상

CEO 급여 비율	7.5%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Recent updates

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

May 10

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Mar 07

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Feb 12

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Dec 16

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Nov 10

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Oct 03

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Jun 28

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Mar 04

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

Oct 12

What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Nov 27

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

Nov 25

CEO 보상 분석

Dave Lennon 의 보수는 Aadi Bioscience 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$69m
Dec 31 2023	US$2m	US$160k	-US$66m

보상 대 시장: Dave 의 총 보상 ($USD 2.14M )은 US 시장( $USD 683.56K ).

보상과 수익: Dave 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Dave Lennon (53 yo)

less than a year

테뉴어

US$2,135,687

보상

Mr. David J. Lennon, Ph.D. also known as Dave, is the Treasurer at Alliance for Regenerative Medicine from April, 2022. He is the CEO of Satellite Bio. He serves as President and CEO & Director at Aadi Bio...

리더십 팀

이름	위치	테뉴어	보상	소유권
Neil Desai	Founder & Executive Chairman	12.7yrs	US$2.16m	7.87% $ 3.1m
David Lennon	President	less than a year	US$2.14m	데이터 없음
Scott Giacobello	CFO, Treasurer	2.6yrs	US$1.97m	0% $ 0
Loretta Itri	Chief Medical Officer	2.7yrs	US$1.48m	0.012% $ 4.9k
Stephen Rodin	Senior VP of Legal & General Counsel	2.3yrs	데이터 없음	데이터 없음
Raymond Steitz	Senior VP of Human Resources & Chief Human Resources Officer	2yrs	데이터 없음	데이터 없음
Bryan Ball	Chief Technical Operations Officer	1.8yrs	데이터 없음	0.41% $ 163.0k

2.3yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: AADI 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Neil Desai	Founder & Executive Chairman	12.7yrs	US$2.16m	7.87% $ 3.1m
David Lennon	President	less than a year	US$2.14m	데이터 없음
Caley Castelein	Independent Chairman of the Board	2.8yrs	US$258.91k	0.080% $ 32.1k
Emma Reeve	Independent Director	2.8yrs	US$240.91k	0% $ 0
Anupam Dalal	Independent Director	2.8yrs	US$235.91k	0.0046% $ 1.8k
Karin Hehenberger	Independent Director	2.8yrs	US$227.41k	0% $ 0
Richard Maroun	Independent Director	7.3yrs	US$240.91k	0% $ 0
Mohammad Hirmand	Independent Director	1.3yrs	US$345.60k	0% $ 0
Behzad Aghazadeh	Independent Director	2.8yrs	US$225.41k	0% $ 0

2.8yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: AADI 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Aadi Bioscience 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Founder & Executive Chairman notifies of intention to sell stock

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Aadi Bioscience, Inc. Announces Chief Executive Officer Changes

Founder notifies of intention to sell stock

Recent updates

Founder & Executive Chairman notifies of intention to sell stock

Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

Consensus revenue estimates decrease by 14%, EPS upgraded

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

New minor risk - Profitability

Forecast to breakeven in 2026

First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023)

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$2.44 loss per share (vs US$2.69 loss in FY 2022)

Aadi Bioscience, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Founder notifies of intention to sell stock

Aadi Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Price target decreased by 67% to US$11.67

Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Founder notifies of intention to sell stock

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

New minor risk - Share price stability

Aadi Bioscience, Inc. Announces Chief Executive Officer Changes

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Founder notifies of intention to sell stock

Consensus EPS estimates fall by 10%

Second quarter 2023 earnings: EPS misses analyst expectations

Aadi Bioscience, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Founder notifies of intention to sell stock

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Consensus revenue estimates increase by 11%, EPS downgraded

Price target decreased by 8.8% to US$38.75

First quarter 2023 earnings released: US$0.57 loss per share (vs US$0.66 loss in 1Q 2022)

Founder notifies of intention to sell stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience, Inc. Announces Management Changes

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aadi Bioscience, Inc. Announces Executive Changes, Effective January 1, 2023

Aadi Bioscience, Inc. Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-Sirolimus at 34th EORTC-NCI-AACR Symposium

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Aadi Bioscience: Taking mTOR Inhibition To The Next Level

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aadi Bioscience, Inc. Reports Impairment of Intangible Asset for the Second Quarter Ended June 30, 2022

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Microcap Value Index

Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience, Inc. Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Present at 2022 ASCO Annual Meeting

Consensus revenue estimates increase by 112%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services

High number of new directors

Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Aadi Bioscience, Inc. Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa

Interim Chief Financial Officer Lance Thibault has left the company

What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

Aadi Bioscience, Inc. Announces FDA Approval of Its First Product Fyarro™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

CEO 보상 분석

CEO

테뉴어

보상